Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i).

Authors:
Hussein A Tawbi Caroline Robert Jan C Brase Daniel Gusenleitner Eduard Gasal James Garrett Alexander Savchenko Güllü Görgün Keith T Flaherty Antoni Ribas Reinhard Dummer Dirk Schadendorf Georgina V Long Paul D Nathan Paolo A Ascierto

J Immunother Cancer 2022 Jun;10(6)

Istituto Nazionale Tumori, IRCCS, Fondazione "G. Pascale", Naples, Italy.

Background: The randomized phase 3 COMBI-i trial did not meet its primary endpoint of improved progression-free survival (PFS) with spartalizumab plus dabrafenib and trametinib (sparta-DabTram) vs placebo plus dabrafenib and trametinib (placebo-DabTram) in the overall population of patients with unresectable/metastatic V600-mutant melanoma. This prespecified exploratory biomarker analysis was performed to identify subgroups that may derive greater treatment benefit from sparta-DabTram.

Methods: In COMBI-i (ClinicalTrials.gov, NCT02967692), 532 patients received spartalizumab 400 mg intravenously every 4 weeks plus dabrafenib 150 mg orally two times daily and trametinib 2 mg orally one time daily or placebo-DabTram. Baseline/on-treatment pharmacodynamic markers were assessed via flow cytometry-based immunophenotyping and plasma cytokine profiling. Baseline programmed death ligand 1 (PD-L1) status and T-cell phenotype were assessed via immunohistochemistry; V600 mutation type, tumor mutational burden (TMB), and circulating tumor DNA (ctDNA) via DNA sequencing; gene expression signatures via RNA sequencing; and CD4/CD8 T-cell ratio via immunophenotyping.

Results: Extensive biomarker analyses were possible in approximately 64% to 90% of the intention-to-treat population, depending on sample availability and assay. Subgroups based on PD-L1 status/TMB or T-cell inflammation did not show significant differences in PFS benefit with sparta-DabTram vs placebo-DabTram, although T-cell inflammation was prognostic across treatment arms. Subgroups defined by V600K mutation (HR 0.45 (95% CI 0.21 to 0.99)), detectable ctDNA shedding (HR 0.75 (95% CI 0.58 to 0.96)), or CD4/CD8 ratio above median (HR 0.58 (95% CI 0.40 to 0.84)) derived greater PFS benefit with sparta-DabTram vs placebo-DabTram. In a multivariate analysis, ctDNA emerged as strongly prognostic (p=0.007), while its predictive trend did not reach significance; in contrast, CD4/CD8 ratio was strongly predictive (interaction p=0.0131).

Conclusions: These results support the feasibility of large-scale comprehensive biomarker analyses in the context of a global phase 3 study. T-cell inflammation was prognostic but not predictive of sparta-DabTram benefit, as patients with high T-cell inflammation already benefit from targeted therapy alone. Baseline ctDNA shedding also emerged as a strong independent prognostic variable, with predictive trends consistent with established measures of disease burden such as lactate dehydrogenase levels. CD4/CD8 T-cell ratio was significantly predictive of PFS benefit with sparta-DabTram but requires further validation as a biomarker in melanoma. Taken together with previous observations, further study of checkpoint inhibitor plus targeted therapy combination in patients with higher disease burden may be warranted.

Trial Registration Number: NCT02967692.

Download full-text PDF

 Source
http://dx.doi.org/10.1136/jitc-2021-004226DOI Listing
June 2022

Publication Analysis

Top Keywords

t-cell inflammation
16
pfs benefit
12
dabrafenib trametinib
12
benefit sparta-dabtram
12
biomarker analyses
12
cd4/cd8 t-cell
8
t-cell ratio
8
cd4/cd8 ratio
8
ratio predictive
8
targeted therapy
8
sparta-dabtram placebo-dabtram
8
randomized phase
8
exploratory biomarker
8
inflammation prognostic
8
v600-mutant melanoma
8
disease burden
8
ctdna shedding
8
t-cell
7
benefit
6
biomarker
5

Keyword Occurance

Similar Publications

Gene expression profiles of ischemic stroke clots retrieved by mechanical thrombectomy are associated with disease etiology.

Authors:
Vincent M Tutino Sarah Fricano Aichi Chien Tatsat R Patel Andre Monteiro Hamid H Rai Adam A Dmytriw Lee D Chaves Muhammad Waqas Elad I Levy Kerry E Poppenberg Adnan H Siddiqui

J Neurointerv Surg 2022 Jun 24. Epub 2022 Jun 24.

Canon Stroke and Vascular Research Center, University at Buffalo, Buffalo, New York, USA.

Background: Determining stroke etiology is crucial for secondary prevention, but intensive workups fail to classify ~30% of strokes that are cryptogenic.

Objective: To examine the hypothesis that the transcriptomic profiles of clots retrieved during mechanical thrombectomy are unique to strokes of different subtypes.

Methods: We isolated RNA from the clots of 73 patients undergoing mechanical thrombectomy. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

Dendrobium nobile protects against ovalbumin-induced allergic rhinitis by regulating intestinal flora and suppressing lung inflammation.

Authors:
Fei-Peng Duan Yi-Sheng Li Tian-Yong Hu Xin-Quan Pan Fang Ma Yue Feng Shu-Qi Qiu Yi-Qing Zheng

Chin J Nat Med 2022 Jun;20(6):443-457

Institute of Otolaryngology, Institute of Hearing and Speech of Sun Yat-sen University, Sun Yat-sen Me-morial Hospital, Sun Yat-sen University, Guangzhou 510520, China. Electronic address:

Antibiotic exposure-induced dysbiosis of the intestinal flora increases the risk of developing allergic rhinitis. Hence, regulating the balance of intestinal flora may be useful for preventing and treating allergic rhinitis. However, the underlying mechanism is unclear. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

A Hemagglutinin 1 Carrying Plant-Based Virus-like Particle Vaccine Generates an Efficacious Cellular Response by Exploiting IL-1 Signaling in Both Adult and Aged Mice.

Authors:
Fernando Alvarez Roman Istomine Hilary Hendin Breanna Hodgins Stephane Pillet Jörg H Fritz Nathalie Charland Brian J Ward Ciriaco A Piccirillo

Immunohorizons 2022 Jun 24;6(6):384-397. Epub 2022 Jun 24.

Department of Microbiology & Immunology, McGill University, Montreal, Quebec, Canada;

Inactivated influenza vaccines have struggled to provide consistent protection in older individuals. Circumventing immune senescence, an aging of the immune response characterized by weak humoral responses to vaccines, and unchecked inflammation during infection require novel immunization strategies. Plant-based virus-like particles (VLPs) bearing recombinant hemagglutinin proteins have been shown to provide protection in older animals in preclinical challenge studies, despite eliciting relatively low or absent humoral responses. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

Age-dependent neurodegeneration and neuroinflammation in a genetic A30P/A53T double-mutated α-synuclein mouse model of Parkinson's disease.

Authors:
Lisa Rauschenberger Jennifer Behnke Alexander Grotemeyer Susanne Knorr Jens Volkmann Chi Wang Ip

Neurobiol Dis 2022 Jun 21:105798. Epub 2022 Jun 21.

Department of Neurology, University Hospital of Würzburg, Josef-Schneider-Straße 11, 97080 Würzburg, Germany. Electronic address:

The pathogenesis of Parkinson's disease (PD) is closely interwoven with the process of aging. Moreover, increasing evidence from human postmortem studies and from animal models for PD point towards inflammation as an additional factor in disease development. We here assessed the impact of aging and inflammation on dopaminergic neurodegeneration in the hmα-SYN-39 mouse model of PD that carries the human, A30P/A53T double-mutated α-synuclein gene. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

Interactions among the mycobiome, bacteriome, inflammation, and diet in people living with HIV.

Authors:
María José Gosalbes Nuria Jimenéz-Hernandéz Elena Moreno Alejandro Artacho Xavier Pons Sonia Ruíz-Pérez Beatriz Navia Vicente Estrada Mónica Manzano Alba Talavera-Rodriguez Nadia Madrid Alejandro Vallejo Laura Luna José A Pérez-Molina Santiago Moreno Sergio Serrano-Villar

Gut Microbes 2022 Jan-Dec;14(1):2089002

Department of Infectious Diseases, IRYCIS, Hospital Ramón y Cajal, Madrid, Spain.

While the intestinal microbiome seems a major driver of persistent immune defects in people with HIV (PWH), little is known about its fungal component, the mycobiome. We assessed the inter-kingdom mycobiome-bacteriome interactions, the impact of diet, and the association with the innate and adaptive immunity in PWH on antiretroviral therapy. We included 24 PWH individuals and 12 healthy controls. Read More

View Article and Full-Text PDF
June 2022
Similar Publications
}